Basal Crypt Dysplasia in Barrett's Esophagus: GUT | July 2026

Introduction:

Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may represent one of the earliest stages of dysplasia in BE.

Why was this review needed?

• Barrett's esophagus and esophageal adenocarcinoma continue to increase worldwide.
• Conventional dysplasia assessment may miss early neoplastic changes confined to the crypt base.
• Diagnostic criteria for crypt dysplasia remain inconsistent.
• Better pathological recognition may improve early cancer detection.
• The biological significance of crypt dysplasia requires clarification.

Key Takeaways:

• Crypt dysplasia is characterized by dysplastic changes confined to the basal crypts, with little or no involvement of the surface epithelium.
• Molecular studies demonstrate that crypt dysplasia shares key genetic alterations, including TP53 mutations and chromosomal instability, with conventional low-grade and high-grade dysplasia.
• High-grade crypt atypia should be recognized as true crypt dysplasia, whereas low-grade crypt atypia requires careful distinction from reactive inflammatory changes.
• Inflammation, ulceration, and erosion should be excluded before diagnosing crypt dysplasia to avoid overdiagnosis.
• Standardized grading into low-grade and high-grade crypt dysplasia offers a practical framework but still requires prospective validation.
• Further studies are needed to determine the natural history, cancer progression risk, and interobserver reproducibility of crypt dysplasia.

Clinical Impact:

Recognition of crypt dysplasia may enable earlier identification of neoplastic transformation in Barrett's esophagus before conventional surface dysplasia becomes evident. As diagnostic criteria become standardized, crypt dysplasia may become an important addition to Barrett's pathology reporting and risk stratification.

Bottom Line:

Basal crypt dysplasia is an emerging early marker of neoplasia in Barrett's esophagus. Although not yet ready for universal adoption, growing molecular and pathological evidence suggests it may become an important component of future Barrett's surveillance and management.